CoChat

Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

The aim of this study was to investigate the efficacy and safety of ondansetron as an augmentative agent to fluvoxamine in the treatment of patients with obsessive-compulsive disorder (OCD). Forty-six men and women, aged 18-60 years, who fulfilled the diagnostic criteria of OCD on the basis of the DSM-IV-TR and had a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 were recruited into the study. The patients randomly received either ondansetron (8 mg/day) or placebo for 8 weeks. All patients received fluvoxamine (100 mg/day) for the first 4 weeks, followed by 200 mg/day for the rest of the trial. The patients were assessed using the Y-BOCS and the adverse event checklists at baseline, and the second, fourth, sixth, and eighth week. Forty-four patients completed the study. The Y-BOCS total score as well as the Y-BOCS obsession subscale score and compulsion subscale score showed significantly greater reduction in the ondansetron group than in the placebo group. There was no significant difference in adverse events between the two groups. In this 8-week double-blind randomized-controlled trial, ondansetron showed significant beneficial effect as an augmentative agent with fluvoxamine in patients with moderate to severe OCD and it was generally well tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000043

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Cited by

See all 48

Metadata

Authors
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S.
Affiliations
  • Academic Center for Education, Culture and Research (IR)
  • Roozbeh Hospital (IR)
  • Tehran University of Medical Sciences (IR)
Corresponding author
Akhondzadeh, Shahin
Venue
International Clinical Psychopharmacology
Published
2014-11
Volume
29
Issue
6
Pages
344-350
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2042008286
Cited by
48
References
56
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 10 · 2016: 4 · 2015: 5
FWCI
7.47
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Yale University
  • Tehran University of Medical Sciences and Health Services
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
ondansetron, fluvoxamine, obsessive-compulsive disorder, drug augmentation, serotonin antagonists, Yale-Brown Obsessive Compulsive Scale, adverse events, drug tolerability
MeSH terms
Adolescent, Adult, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Placebos, Serotonin Antagonists, Fluvoxamine, Treatment Outcome, Ondansetron, Selective Serotonin Reuptake Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder. https://app.cochat.ai/papers/10.1097/yic.0000000000000043
The paper
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014). Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive–compulsive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.